Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

NCT04790474 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

OTHER_GOV

Sponsor class

Conditions

Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions

DRUG: ixazomib-pomalidomide-dexamethasone

Sponsor

Tel-Aviv Sourasky Medical Center